SecBot SecBot

CLNN

Clene Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001822791 Biotech & Drug Discovery
$3.84 −0.04 (−1.03%)
Oct 26 4:00 PM ET · prev $3.88
Market cap
$55.2M
Micro cap
Consensus
Buy
91% Buy or better · 11 analysts
Median target
$30.00
+681% · range $20.00–50.00
Next earnings
Nov 10
in 15 days · EPS est. −$0.47
1 year
−54.9%
from $8.51 · Oct 27
30 days
−5.4%
from $4.06
52-week range
$3.10–12.50
−69% from high · low Oct 16
Avg volume 20D
96.3K
Oct 5 spike 278.2K
Short interest
880.7K
≈6.2% of shares · −3.8%
Days to cover
7.5
at average volume
Insider net
−$2.4M
0 buyers · 1 seller · since Mar 31
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 9 reports · 90 days
Balance 2 bearish · 3 bullish · 2 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 5/9 ·Next Earnings date, Nov 10, 2026
Strongest BULLISH Clene Inc. announced it has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $2.4M.

  • InstitutionsMIXED

    Q2 2026: 4 added (0 new), 4 trimmed or exited.

  • AnalystsBULLISH

    10 of 11 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.280 → −$0.475 over 90 days. 0 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest −3.8% to 880.7K shares. 7.5 days to cover, ≈6.2% of shares.

  • TrendDOWNTREND

    3% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
Ensign Peak Advisors, IncADD348,062$2.1M
BlackRock, Inc.ADD61,559$378.9K
VANGUARD FIDUCIARY TRUST COADD57,765$355.5K
PEAK6 LLCTRIM30,012$184.7K
Arax Advisory PartnersDOUBLED11,140$68.6K
OSAIC HOLDINGS, INC.TRIM1,055$6.5K
UBS Group AGNEAR_EXIT351$2.2K
BNP PARIBAS FINANCIAL MARKETSTRIM13$80.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 91% rate it Buy or better
Strong Buy2Buy8Hold1Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +681%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 19, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
May 4, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
May 4, 2026D. Boral Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$2.4M
sold · 1 insider
DateInsiderTypeValue
Oct 20, 2026
Etherington Robert Dee
President & CEO
AWARD55,000 sh
Oct 20, 2026
Mortenson Mark
Chief Science Officer
AWARD30,000 sh
Oct 20, 2026
BROWN MORGAN R
Chief Financial Officer
AWARD20,000 sh
Sep 16, 2026
Mosca Alison
Director
AWARD$650.0K
Sep 16, 2026
Etherington Robert Dee
President & CEO
AWARD$50.0K
Sep 16, 2026
MATLIN DAVID J
Director
AWARD$1.4M
Aug 13, 2026
WILCOX REED N
Director
AWARD3,514 sh
Aug 13, 2026
McLaughlin Vallerie
Director
AWARD3,514 sh

Earnings setup

Estimates
Nov 10
reports in 15 days
−$0.47
EPS estimate, this quarter
−70%
estimate change, 90 days
0↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.47-$0.49–-$0.46-69.6%$59.2K
Next Q-$0.44-$0.53–-$0.35-69.2%$67.2K
Current FY-$2.62-$2.78–-$2.46-86.5%$249.4K
Next FY-$2.44-$3.46–-$1.42-36.3%$23.3M

Short side

FINRA· Sep 30, 2026
880,688
shares short
-3.8%
vs prior settlement
7.5
days to cover
≈6.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 Insider
Etherington Robert Dee was granted 55,000 shares
President & CEO
Oct 20, 2026 Insider
Mortenson Mark was granted 30,000 shares
Chief Science Officer
Oct 20, 2026 Insider
BROWN MORGAN R was granted 20,000 shares
Chief Financial Officer
Oct 19, 2026 SEC
Clene Inc. entered into a subaward amendment with NYU Grossman School of Medicine for the fourth year of its NIH…
8-K — Impact 3/10
Oct 19, 2026 SEC
Clene Inc. announced it has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval of CNM-Au8…
8-K — Impact 7/10
Oct 19, 2026 Press
Clene Inc. announced it has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval of CNM-Au8…
Impact 8/10
Oct 19, 2026 FDA
Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS
NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker da
Oct 13, 2026 SEC
Empery Asset Management, LP filed an amendment to its Schedule 13G, reporting a passive stake of 1.56% in Clene Inc…
SC 13G/A — Impact 3/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
CLNN Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Oct 19, 2026
FDA
Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS
NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes SALT LAKE CITY, Oct…
Sep 21, 2026
Press release
Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
SALT LAKE CITY, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on ALS, today announced…
Aug 17, 2026
Earnings date
CLNN Q2 2026 Earnings Scheduled — 2026-08-17
Aug 14, 2026
Earnings
Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
SALT LAKE CITY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced its second quarter 2026 financial results and provided…
Aug 12, 2026
Earnings date
CLNN Q2 2026 Earnings Scheduled — 2026-08-12

SecBot reports

15 filings · 2 press releases · 5 bullish · 4 bearish · 3 mixed · 3 neutral
All CLNN filing & press-release reports (17)